It's fairly rare for a judge to order the disclosure of internal FDA discussions. Then again it's fairly rare for biopharma executives to be facing criminal penalties. The FDA discussions may show bias on their part but I doubt it would offer any proof of innocence on the part of Nader or Kazempour. Without that the judge is not going to order the release of those documents.

Thinking about it for a minute, it's possible Nader and Kazempour's lawyers will say that the FDA discussion about the viability of the BLA was the basis for the charging documents. So we might see what was said after all.